Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
Enhance the predictive accuracy of cardiac safety assessments to ensure safer drug development and reduce the likelihood of late-stage failures due to cardiac toxicityEvaluating multiple endpoints including APD20/50/90 (action potential duration at different repolarisation stages), rise time, beat rate, and triangulation is crucial for assessing cardiovascular risk in drug discovery. It provides a comprehensive understanding of a compound's effects on cardiac electrophysiology. These endpoints collectively help identify proarrhythmic risks by detecting subtle changes in ion channel function that may not be apparent from a single parameter. APD20/50/90 measurements assess repolarisation dynamics, crucial for detecting the risk of QTc prolongation risks and early afterdepolarizations (EADs. Rise time reflects sodium channel activity and depolarization efficiency, while beat rate monitors drug-induced chronotropic effects. Triangulation (the difference between APD90 and APD30) is a key indicator of repolarization instability linked to Torsades de Pointes (TdP) risk.
By analysing multiple endpoints simultaneously, researchers can enhance the predictive accuracy of cardiac safety assessments, ensuring safer drug development and reducing the likelihood of late-stage failures due to cardiac toxicity.
Read more about our hiPSC cardiomyocyte assay.
Reliable, high-throughput KV7 assays paired with expert interpretation enable faster progression of pain and epilepsy drug discovery programmes.
By accurately defining the drug exposure levels that affect QRS duration, researchers can establish safety margins, prioritise lower-risk compounds, and reduce the chance of late-stage failures due to cardiac toxicity